Phase 3 trial of eribulin versus dacarbazine for the treatment of advanced liposarcoma or leiomyosarcoma | Prof Patrick Schöffski at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium, discusses the results of a randomised, open-label, multicentre, phase 3 trial of the microtubule dynamics inhibitor, eribulin, versus dacarbazine for the treatment of patients with advanced liposarcoma or leiomyosarcoma.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews